Novo Holdings expands Korea engagement as part of long-term Asia investment strategy

Working with local partners to explore opportunities in Korea’s healthcare ecosystem

Singapore, 28 April 2026 – Novo Holdings is expanding its engagement with South Korea’s healthcare and life sciences ecosystem as part of its long-term investment strategy in Asia. Korea’s strengths in advanced manufacturing, life sciences tools and diagnostics, and innovation-led healthcare platforms make it an increasingly relevant market as Novo Holdings continues to evaluate opportunities across the region.

As Novo Holdings deepens its understanding of the Korean market, it is engaging with local stakeholders and partners to enhance market insight and explore areas of potential collaboration. One such partner is Premier Partners, a Korea-based investment firm with experience across healthcare and related sectors, with whom Novo Holdings is working to explore opportunities aligned with its long-term investment priorities.

Premier Partners brings experience across healthcare private equity and venture investing in Korea. Its private equity platform has backed a range of healthcare and medtech companies, including in areas such as medical devices, pharmaceuticals and aesthetics. In parallel, Premier Partners has built an active venture capital platform focused on biotechnology, investing across multiple dedicated funds in drug development and platform-based innovation.

“Korea stands out in Asia for the depth and sophistication of its healthcare and life sciences ecosystem,” said Amit Kakar, Managing Partner and Head of Asia, Novo Holdings. “Across the region, we are seeing a clear shift toward innovation-driven healthcare platforms and enabling infrastructure. From an Asia perspective, Korea is increasingly important, and we are excited to deepen our engagement with the market as part of our long-term investment approach.”

Navjeewan Khosla, Partner, Novo Holdings Asia, added: “In Korea, our focus is on areas where the country has demonstrated global competitiveness, including advanced manufacturing, tools and diagnostics, and other capabilities that underpin healthcare delivery at scale. Working closely with experienced local partners like Premier Partners helps us develop a more nuanced understanding of the opportunity set and where collaboration could be most impactful over the long term.”

Through its Asia platform, Novo Holdings continues to evaluate healthcare and life sciences opportunities across the region, with an emphasis on strong fundamentals, credible management teams, and the potential to generate sustainable long-term value.